Basic Information
| ID | DRAMP20957 |
|---|
| Sequence | FFSLIPKLVKGLISAFK |
|---|
| Length | 17 |
|---|
| Name | StigA6 |
|---|
| Source | Synthetic construct |
|---|
| Activity | Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram-, Antifungal, Antiparasitic, Antiproliferative |
|---|
| Pathogen | [Ref.29670004] Gram-positive bacteria: Staphylococcus aureus ATCC 29213 (MIC=2.34 μM), Staphylococcus epidermidis ATCC 122225 (MIC=9.38 μM), Enterococcus faecalis ATCC 4028 (MIC=1.17 μM);##Gram-negative bacteria: Escherichia coli ATCC 25922 (MIC=4.69 μM), Enterobacter cloacae ATCC 13047 (MIC=18.75 μM), Pseudomonas aeruginosa ATCC 27853 (MIC=9.38 μM);##yeasts: Candida albicans ATCC 90028 (MIC=9.38 μM), Candida krusei ATCC 6258 (MIC=37.5 μM), Candida glabrata ATCC 90030 (MIC=18.75 μM);##StigA6 inhibit 100% of the epimastigote forms of Trypanosoma cruzi growth at 2.5 µM;##HeLa cell line: IC50=14.01 µM |
|---|
| Hemolytic Activity | [Ref.29670004] Hemolysis 0% at 1.17 μM, hemolysis 2% at 2.34 μM, hemolysis 15% at 4.69 μM, hemolysis 27% at 9.38 μM, hemolysis 30% at 18.75 μM, hemolysis 30% at 37.50 μM, hemolysis 27% at 75.00 μM against human red blood cells |
|---|
| Cytotoxicity | [Ref.29670004] The cell viability of HeLa cell lines is 19%, 15%, 11%, 29%, 9%, 13% and 8% at peptide concentrations of 2, 4, 8, 10, 15, 20 and 40 μM. ##The cell viability of 3T3 cell lines is 81%, 73%, 69%, 61%, 51%, 20% and 15% at peptide concentrati |
|---|
| N-terminal Modification | Free |
|---|
| C-terminal Modification | Amidation |
|---|
| Linear/Cyclic/Branched | Linear |
|---|
| Uniprot |
|
|---|
| PDB |
|
|---|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 29670004 |
|---|
